Involvement of Plasmalogens in Neurological Disorders
Publisher
Springer New York
Reference120 articles.
1. Bams-Mengerink A. M., Majoie C. B., Duran M., Wanders R. J., Van Hove J., Scheurer C. D., Barth P. G., and Poll-The B. T. (2006). MRI of the brain and cervical spinal cord in rhizomelic chondrodysplasia punctata. Neurology 66:798–803.
2. Berry K. A. Z. and Murphy R. C. (2005). Free radical oxidation of plasmalogen glycerophosphocholine containing esterified docosahexaenoic acid: Structure determination by mass spectrometry. Antioxidants and Redox Signaling 7:157–169.
3. Bichenkov E. and Ellingson J. S. (1999). Temporal and quantitative expression of the myelin-associated lipids, ethanolamine plasmalogen, galactocerebroside, and sulfatide, in the differentiating CG-4 glial cell line. Neurochem. Res. 24:1549–1556.
4. Brosche T., Platt D., and Knopf B. (2002). Decreased concentrations of serum phospholipid plasmalogens indicate oxidative burden of uraemic patients undergoing haemodialysis. Nephron 90:58–63.
5. Brosche T., Brueckmann M., Haase K. K., Sieber C., and Bertsch T. (2007). Decreased plasmalogen concentration as a surrogate marker of oxidative stress in patients presenting with acute coronary syndromes or supraventricular tachycardias. Clin. Chem. Lab. Med. 45:689–691.